Literature DB >> 17954782

T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis.

M Salajegheh1, G Rakocevic, R Raju, A Shatunov, L G Goldfarb, M C Dalakas.   

Abstract

BACKGROUND: Sporadic IBM (sIBM) is characterized by invasion of non-necrotic MHC-I class-expressing muscle fibers by clonally expanded CD8+ cells. Whether the endomysial cells expand in situ or are recruited from the circulation is unclear.
METHODS: We used CDR3 spectratyping of the T cell receptor (TCR) V beta chains to determine clonal expansion of T cells in simultaneously obtained muscle and peripheral blood lymphocytes (PBL) from 12 patients with sIBM, and compared the difference between the two compartments. To determine whether the identified clones belonged to autoinvasive T cells, we performed immunohistochemistry on the same muscle specimens. Spectratyping was repeated in four muscle biopsies 1 year after the first.
RESULTS: In control PBL, all 24 TCR V beta subfamilies had a polyclonal or Gaussian distribution. In sIBM PBL, 5% of the V beta subfamilies demonstrated a single and 16% up to three peaks. In contrast, in their corresponding muscles, 27% (p = 0.0003) of the V beta subfamilies demonstrated a single and 71% (p < 0.0001) up to three peaks. Among the amplified subfamilies, V beta 9, 10, 11, 16, 18, 23, and 24 showed the highest degree of restriction within muscle. Immunohistochemistry demonstrated that the clonally expanded CD8+ cells were autoinvasive. In follow-up biopsies the clonality persisted with an unchanged degree of restriction, but not always of the same subfamilies, suggesting epitope spreading.
CONCLUSION: In sporadic inclusion body myositis, the endomysial T cells are specifically recruited to the muscle or expand in situ. The restriction of multiple V beta subfamilies and their change over time suggests recognition of various local antigens and epitope spreading.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17954782     DOI: 10.1212/01.wnl.0000265398.77681.09

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

Review 2.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

3.  Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells.

Authors:  Namita A Goyal; Gérald Coulis; Jorge Duarte; Philip K Farahat; Ali H Mannaa; Jonathan Cauchii; Tyler Irani; Nadia Araujo; Leo Wang; Marie Wencel; Vivian Li; Lishi Zhang; Steven A Greenberg; Tahseen Mozaffar; S Armando Villalta
Journal:  Neurology       Date:  2022-02-07       Impact factor: 9.910

Review 4.  Inclusion body myositis: review of recent literature.

Authors:  Steven A Greenberg
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

Review 5.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 6.  Immunotherapies for Immune-Mediated Myopathies: A Current Perspective.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 7.  T cells in myositis.

Authors:  Vivianne Malmström; Paulius Venalis; Inka Albrecht
Journal:  Arthritis Res Ther       Date:  2012-12-28       Impact factor: 5.156

8.  Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA.

Authors:  Mark A Price; Victoria Barghout; Olivier Benveniste; Lisa Christopher-Stine; Alastair Corbett; Marianne de Visser; David Hilton-Jones; John T Kissel; Thomas E Lloyd; Ingrid E Lundberg; Francis Mastaglia; Tahseen Mozaffar; Merrilee Needham; Jens Schmidt; Kumaraswamy Sivakumar; Carla DeMuro; Brian S Tseng
Journal:  J Neuromuscul Dis       Date:  2016-03-03

9.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

Authors:  Marinos C Dalakas; Goran Rakocevic; Jens Schmidt; Mohammad Salajegheh; Beverly McElroy; Michael O Harris-Love; Joseph A Shrader; Ellen W Levy; James Dambrosia; Robert L Kampen; David A Bruno; Allan D Kirk
Journal:  Brain       Date:  2009-05-19       Impact factor: 13.501

Review 10.  Developments in the scientific and clinical understanding of inflammatory myopathies.

Authors:  Ingrid E Lundberg; Cecilia Grundtman
Journal:  Arthritis Res Ther       Date:  2008-10-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.